Department of Clinical Laboratory, The Affiliated Hospital to Changchun, University of Chinese Medicine, Changchun, China.
Department of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun, China.
Rev Med Virol. 2024 Jan;34(1):e2503. doi: 10.1002/rmv.2503.
The diverse and severe nature of neurological manifestations associated with coronavirus disease 2019 (Covid-19) has garnered increasing attention. Exploring the potential to decrease neurological complications in Covid-19 patients involves targeting the mammalian target of rapamycin (mTOR) pathway as a therapeutic strategy. The mTOR pathway, widely recognised for its central role in essential cellular processes like synthesising proteins, facilitating autophagy, and modulating immune responses, has implications in various neurological disorders. Drawing parallels between these disorders and the observed neurological complications in Covid-19, we present a comprehensive review on the current understanding of mTOR signalling in the context of severe acute respiratory syndrome coronavirus 2 infection and neuroinflammation.
与 2019 年冠状病毒病（COVID-19）相关的神经表现具有多样性和严重性，这引起了越来越多的关注。探索降低 COVID-19 患者发生神经并发症的可能性，需要将雷帕霉素靶蛋白（mTOR）途径作为一种治疗策略。mTOR 途径在合成蛋白质、促进自噬和调节免疫反应等基本细胞过程中发挥着核心作用，广泛受到关注，它与各种神经疾病有关。我们将这些疾病与 COVID-19 中观察到的神经并发症进行类比，全面综述了严重急性呼吸综合征冠状病毒 2 感染和神经炎症背景下 mTOR 信号的最新认识。
